Zusammenfassung
Hintergrund
Der persistierenden chronischen Rhinosinusitis (CRS) kann, insbesondere wenn sie mit einer häufig rezidivierenden Polyposis nasi et sinuum, einem Asthma bronchiale und einer Überempfindlichkeitsreaktion auf Acetylsalicylsäure (ASS) und anderen nichtsteroidalen Antiphlogistika gemeinsam einhergeht, das Analgetika-Intoleranz-Syndrom (AIS) zu Grunde liegen. Die Pathogenese dieses Syndroms wird auf eine Fehlleitung des Arachidonsäurestoffwechsels mit der Folge einer erhöhten Leukotrienproduktion zurückgeführt.
Methoden
Die Diagnosestellung ist bei häufig unvollständiger Symptomtrias im Anfangsstadium der Erkrankung erschwert. Ziel sollte dennoch eine frühzeitige Einleitung einer spezifischen Therapie sein.
Ergebnisse
Zur Behandlung der CRS haben sich eine chirurgische Sanierung der Nasennebenhöhlen, eine antiinflammatorisch-medikamentöse Therapie und die adaptive Desaktivierung als einzige kausale Behandlungsmöglichkeit bewährt.
Schlussfolgerung
Die adaptive Desaktivierung zeigt nach aktueller Studienlage positive Effekte auch bei zuvor langwierigen rhinosinusitischen Beschwerden. Zusammen mit weiteren symptomorientierten Maßnahmen kann so eine Reduktion der sinunasalen Symptome erreicht werden.
Abstract
Background
A differential diagnosis of persistent chronic rhinosinusitis is ASA-intolerance syndrome (AIS), also known as Aspirin®‑exacerbated respiratory disease (AERD), Samter-Trias (Samter’s disease, Morbus Widal). Particularly in cases of frequent recurrency of nasal polyps in combination with bronchial asthma and hypersensitivity reactions to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAR) can often be referred to an underlying AIS. The pathogenesis of this syndrome is attributed to a misallocation of the arachidonic acid metabolism, resulting in an increased leukotriene production.
Methods
The diagnosis may be difficult in the early stages of the disease with incomplete triad of symptoms.
Results
Therapy may consist of paranasal sinuses surgery, drug therapy and adaptive deactivation as the only causal treatment option for patients with AIS.
Conclusion
For adaptive desactivation, positive effects were actually shown even in patients with long-term recurrent or persistent complaints of chronic rhinosinusitis.
Abbreviations
- AIS:
-
Analgetika-Intoleranz-Syndrom
- ASS:
-
Acetylsalicylsäure
- CAST:
-
Cellular allergen stimulation test
- CRS:
-
Chronische Rhinosinusitis
- CRSwNP:
-
Chronic rhinosinusitis with nasal polyposis, Chronische Rhinosinusitis mit nasaler Polyposis
- FESS:
-
Functional Endoscopic Sinus Surgery, funktionelle endoskopische Nasennebenhöhlenchirurgie
- FET:
-
Funktioneller Eikosanoidtest
- GKS:
-
Glukokortikosteroide
- LRA:
-
Leukotrien-Rezeptor-Antagonist
- nGKS:
-
Nasale Glukokortikosteroide
- NNH:
-
Nasennebenhöhle
- NSAR:
-
Nichtsteroidale Antiphlogistika
Literatur
Widal F, Abrami P, Lermoyez J (1993) Anaphylaxie et idiosyncrasie. Allergy Proc 14(5):373–376 (discussion 371–372)
Pfaar O, Spielhaupter M, Klimek L (2005) Max Samter – ein Pionier und Wegbereiter der modernen Allergologie und Rhinologie. Allergo J 8:630–634
Zeitz HJ (1988) Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter’s syndrome. Clin Chest Med 9(4:567–576
Schapowal A (1998) Pseudoallergische Reaktionen auf nicht steroidale Antiphlogistika. In: Heppt W, Bachert C (Hrsg) Praktische Allergologie – Schwerpunkt HNO-Heilkunde. Thieme, Stuttgart, S 233–238
Morwood K, Gillis D, Smith W, Kette F (2005) Aspirin-sensitive asthma. Intern Med J 35(4):240–246
Szczeklik A, Nizankowska E, Duplaga M (2000) Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 16(3):432–436
Hosemann W, Kuhnel T, Pfeifer M (2000) Analgesic intolerance and nasal polyps. Laryngorhinootologie 79(1):53–65
Hedman J, Kaprio J, Poussa T, Nieminen MM (1999) Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 28(4):717–722
Berges-Gimeno MP, Simon RA, Stevenson DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111(1):180–186
Fokkens W, Lund V, Mullol J (2007) European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 2007(20):1–136
Gosepath J, Pogodsky T, Mann WJ (2008) Characteristics of recurrent chronic rhinosinusitis after previous surgical therapy. Acta Otolaryngol 128(7):778–784
Berges-Gimeno MP, Simon RA, Stevenson DD (2002) The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89(5):474–478
Caplin I, Haynes JT, Spahn J (1971) Are nasal polyps an allergic phenomenon? Ann Allergy 29(12):631–634
Larsen K (1996) The clinical relationship of nasal polyps to asthma. Allergy Asthma Proc 17(5):243–249
Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW (2005) Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 94(6):652–657
Ogino S, Harada T, Okawachi I, Irifune M, Matsunaga T, Nagano T (1986) Aspirin-induced asthma and nasal polyps. Acta Otolaryngol Suppl 430:21–27
Settipane GA (1997) Nasal polyps: epidemiology, pathogenesis and treatment. Oceanside Publications, Rhode Island
Settipane GA, Chafee FH, Klein DE (1974) Aspirin intolerance. II. A prospective study in an atopic and normal population. J Allergy Clin Immunol 53(4):200–204
Stevenson DD (2009) Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 9(2):155–163
Szczeklik A, Stevenson DD (2003) Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 111(5):913–921 (quiz 922)
Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T (1996) Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 98(3):678–685
Hillerdal G, Lindholm H (1984) Laryngeal edema as the only symptom of hypersensitivity to salicylic acid and other substances. J Laryngol Otol 98(5):547–548
Baenkler HW (2006) Intoleranz gegenüber Salicylaten/Analgetika. Bayr Internist 5:251–260
Buss YA, Garrelfs UC, Sticherling M (2007) Chronic urticaria – which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients. J Dtsch Dermatol Ges 5(1):22–29
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F (2002) NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 3(9):599–607
Babu KS, Salvi SS (2000) Aspirin and asthma. Chest 118(5):1470–1476
Dollner R, Klimek L, Pfaar O, Stuck BA, Hörmann K (2007) In-vitro-Testverfahren bei Analgetikaintoleranz. Allergologie 30(7):240–248
Baenkler HW (2008) Salicylate intolerance: pathophysiology, clinical spectrum, diagnosis and treatment. Dtsch Arztebl Int 105(8):137–142
Klimek L, Goebel U, Glowania A (2012) Management of anaphylaxis: part 2: treatment and emergency equipment. HNO 60(12):1103–1113
Albu S, Tomescu E, Mexca Z, Nistor S, Necula S, Cozlean A (2004) Recurrence rates in endonasal surgery for polyposis. Acta Otorhinolaryngol Belg 58(1):79–86
Stuck BA, Bachert C, Federspil P, Hosemann W, Klimek L, Mosges R et al (2007) Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery. HNO 55(10):758–777
Gosepath J, Mann WJ (2005) Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ORL J Otorhinolaryngol Relat Spec 67(3):125–136
Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW (2011) Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol 120(3):162–166
McMains KC, Kountakis SE (2006) Medical and surgical considerations in patients with Samter’s triad. Am J Rhinol 20(6):573–576
Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE (1999) Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin‑2, and monocyte-chemotactic protein‑4 in human airway inflammation with eosinophilia. J Immunol 163(3):1545–1551
Hissaria P, Smith W, Wormald PJ, Taylor J, Vadas M, Gillis D et al (2006) Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol 118(1):128–133
Benitez P, Alobid I, de Haro J, Berenguer J, Bernal-Sprekelsen M, Pujols L et al (2006) A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. Laryngoscope 116(5):770–775
Karlsson G, Rundcrantz H (1982) A randomized trial of intranasal beclomethasone dipropionate after polypectomy. Rhinology 20(3):144–148
Virolainen E, Puhakka H (1980) The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. Rhinology 18(1):9–18
Dingsor G, Kramer J, Olsholt R, Soderstrom T (1985) Flunisolide nasal spray 0.025 % in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study. Rhinology 23(1):49–58
Drettner B, Ebbesen A, Nilsson M (1982) Prophylactive treatment with flunisolide after polypectomy. Rhinology 20(3):149–158
Hartwig S, Linden M, Laurent C, Vargo AK, Lindqvist N (1988) Budesonide nasal spray as prophylactic treatment after polypectomy (a double blind clinical trial). J Laryngol Otol 102(2):148–151
Stjarne P, Olsson P, Alenius M (2009) Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 135(3):296–302
Sastre J, Mosges R (2012) Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 22(1):1–12
Klimek L, Hogger P, Pfaar O (2012) Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis. HNO 60(7):611–617
Bachert C, Geveart P (1999) Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators. Allergy 54(Suppl 57):116–123
Shikani AH, Kourelis K, Rohayem Z, Basaraba RJ, Leid JG (2012) Topical gel therapy for sinonasal polyposis in Samter’s triad: preliminary report. Ann Otol Rhinol Laryngol 121(11):719–724
Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M et al (2002) Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165(1):9–14
Lipworth BJ (1999) Leukotriene-receptor antagonists. Lancet 353(9146):57–62
Pauli C, Fintelmann R, Klemens C, Hilgert E, Jund F, Rasp G et al (2007) Polyposis nasi – improvement in quality of life by the influence of leukotrien receptor antagonists. Laryngorhinootologie 86(4):282–286
Yazici ZM, Sayin I, Bozkurt E, Kayhan FT (2011) Effect of montelukast on quality of life in subjects with nasal polyposis accompanying bronchial asthma. Kulak Burun Bogaz Ihtis Derg 21(4):210–214
Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA (1996) Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 98(4):751–758
Sweet JM, Stevenson DD, Simon RA, Mathison DA (1990) Long-term effects of aspirin desensitization – treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 85(1 Pt 1):59–65
Schmitz-Schumann M, Schaub E, Virchow C (1982) Inhalation provocation test with lysine-acetylsalicylic acid in patients with analgetics-induced asthma (author’s transl). Prax Klin Pneumol 36(1):17–21
Stevenson DD, Simon RA, Mathison DA (1980) Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 66(1):82–88
Forer B, Kivity S, Sade J, Landsberg R (2011) Aspirin desensitization for ASA triad patients – prospective study of the rhinologist’s perspective. Rhinology 49(1):95–99
Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kielbasa B (2004) Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 10(1):51–56
Zeiss CR, Lockey RF (1976) Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 57(5):440–448
Parikh AA, Scadding GK (2005) Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 115(8):1385–1390
White A, Ludington E, Mehra P, Stevenson DD, Simon RA (2006) Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 97(5):688–693
Gosepath J, Schafer D, Mann WJ (2002) Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100 mg of aspirin a day. Laryngorhinootologie 81(10):732–738
McMullan KL, Wedner HJ (2013) Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol 36(1):25–30
Pfaar O, Spielhaupter M, Wrede H (2006) Aspirin desensitization on patients with aspirin intolerance and nasal polyps – a new therapeutic approach by the intravenous route. Allergologie 29(8):322–331
Klimek L, Pfaar O (2009) Aspirin intolerance: does desensitization alter the course of the disease? Immunol Allergy Clin North Am 29(4):669–675
Pfaar O, Klimek L (2006) Aspirin desensitization in aspirin intolerance: update on current standards and recent improvements. Curr Opin Allergy Clin Immunol 6(3):161–166
Umbreit C, Virchow JC, Thorn C, Hormann K, Klimek L, Pfaar O (2010) Aspirin-Intolerance-Syndrom : a common and interdisciplinary disease. Internist (Berl) 51(9):1196–1198 (1200–1191)
Lee JY, Simon RA, Stevenson DD (2007) Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 119(1):157–164
Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H et al (2008) Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 63(9):1228–1234
Havel M, Ertl L, Braunschweig F, Markmann S, Leunig A, Gamarra F et al (2013) Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol 270(2):571–578
Comert S, Celebioglu E, Yucel T, Erdogan T, Karakaya G, Onerci M et al (2013) Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy 68(11):1443–1451
Fruth K, Pogorzelski B, Schmidtmann I, Springer J, Fennan N, Fraessdorf N et al (2013) Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 68(5):659–665
Weber R, Trautmann A, Randerath W, Heppt W, Hosemann W (2012) Aspirin desensitization: therapy options in patients with aspirin-exacerbated respiratory disease. HNO 60(4):369–383
Rizk H (2011) Role of aspirin desensitization in the management of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 19(3):210–217
Tournoij E, Peters RJ, Langenberg M, Kanhai KJ, Moll FL (2009) The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg 37(5):597–603
Cahill KN, Bensko JC, Boyce JA, Laidlaw TM (2015) Prostaglandin D2: A dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 135(1):245–252
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Kirsche und L. Klimek geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Kirsche, H., Klimek, L. ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis. HNO 63, 357–363 (2015). https://doi.org/10.1007/s00106-015-0008-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-015-0008-7